2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
2seventy bio, Inc. (TSVT) Tops Q3 EPS by 36c
November 14, 2023 7:04 AM EST2seventy bio, Inc. (NASDAQ: TSVT) reported Q3 EPS of ($1.40), $0.36 better than the analyst estimate of ($1.76). Revenue for the quarter came in at $12 million versus the consensus estimate of $13.4 million.
For earnings history and earnings-related data on 2seventy bio, Inc. (TSVT) click here.
... More